- Home
- RAPT
as 07-26-2024 4:00pm EST
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 114.8M | IPO Year: | 2019 |
| Target Price: | $18.00 | AVG Volume (30 days): | 434.4K |
| Analyst Decision: | Hold | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.61 - $27.35 | Next Earning Date: | 08-09-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of RAPT Therapeutics Inc. (RAPT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brockstedt Dirk G. | RAPT | CHIEF SCIENTIFIC OFFICER | Jan 5 '24 | Sell | $22.78 | 898 | $20,456.44 | 27,820 | SEC Form 4 |
| HO WILLIAM | RAPT | Chief Medical Officer | Dec 21 '23 | Sell | $21.68 | 2,500 | $54,200.00 | 15,020 | SEC Form 4 |
| HO WILLIAM | RAPT | Chief Medical Officer | Nov 28 '23 | Sell | $13.72 | 1,500 | $20,580.00 | 17,520 | SEC Form 4 |
Latest RAPT Therapeutics Inc. News
RAPT Breaking Stock News: Dive into RAPT Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
RAPT Therapeutics to Cut 40% Workforce -- Shares Down
Insider Monkey
a month ago
Should You Sell Your Stake in RAPT Therapeutics (RAPT)?
Zacks
a month ago
Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround
Zacks
2 months ago
Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MT Newswires
2 months ago
Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform
Zacks
2 months ago
Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks
Simply Wall St.
2 months ago
Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation
GuruFocus.com
3 months ago
RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview
Compare RAPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RAPT RAPT Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.